STAAR Surgical Company (STAA) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
STAAR Surgical Company stock (STAA) is currently trading at $19.19. STAAR Surgical Company PS ratio (Price-to-Sales) is 3.62. Analyst consensus price target for STAA is $19.05. WallStSmart rates STAA as Sell.
- STAA PE ratio analysis and historical PE chart
- STAA PS ratio (Price-to-Sales) history and trend
- STAA intrinsic value — DCF, Graham Number, EPV models
- STAA stock price prediction 2025 2026 2027 2028 2029 2030
- STAA fair value vs current price
- STAA insider transactions and insider buying
- Is STAA undervalued or overvalued?
- STAAR Surgical Company financial analysis — revenue, earnings, cash flow
- STAA Piotroski F-Score and Altman Z-Score
- STAA analyst price target and Smart Rating
STAAR Surgical Company
📊 No data available
Try selecting a different time range
Smart Analysis
STAAR Surgical Company (STAA) · 10 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in peg ratio, institutional own.. Concerns around return on equity and operating margin. Mixed signals suggest waiting for clearer direction before acting.
STAAR Surgical Company (STAA) Key Strengths (2)
Growing significantly faster than its price suggests
110.44% of shares held by major funds and institutions
STAAR Surgical Company (STAA) Areas to Watch (8)
Company is destroying shareholder value
Losing money on operations
Earnings declining -10.50%, profits shrinking
Company is losing money with a negative profit margin
Small-cap company with higher risk but more growth potential
Revenue is fairly priced at 3.62x sales
Fairly priced relative to book value
Solid revenue growth at 18.10% per year
Supporting Valuation Data
STAAR Surgical Company (STAA) Detailed Analysis Report
Overall Assessment
This company scores 42/100 in our Smart Analysis, earning a D grade. Out of 10 metrics analyzed, 2 register as strengths (avg 10.0/10) while 8 fall into concern territory (avg 2.9/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on PEG Ratio, Institutional Own.. Valuation metrics including PEG Ratio (0.76) suggest the stock is attractively priced.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, EPS Growth. Some valuation metrics including Price/Sales (3.62), Price/Book (2.52) suggest expensive pricing. Growth concerns include Revenue Growth at 18.10%, EPS Growth at -10.50%, which may limit upside. Profitability pressure is visible in Return on Equity at -21.70%, Operating Margin at -18.90%, Profit Margin at -33.60%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -21.70% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 18.10% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
STAA Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
STAA's Price-to-Sales ratio of 3.62x trades 39% below its historical average of 5.96x (21th percentile). The current valuation is 83% below its historical high of 21.67x set in Sep 2018, and 514% above its historical low of 0.59x in Apr 2009. Over the past 12 months, the PS ratio has compressed from ~4.3x as trailing revenue scaled faster than the stock price.
Compare STAA with Competitors
Top MEDICAL INSTRUMENTS & SUPPLIES stocks by market cap
Compare any two stocks →WallStSmart Analysis Synopsis
Data-driven financial summary for STAAR Surgical Company (STAA) · HEALTHCARE › MEDICAL INSTRUMENTS & SUPPLIES
The Big Picture
STAAR Surgical Company is a strong growth company balancing expansion with improving profitability. Revenue reached 239M with 18% growth year-over-year. The company is currently unprofitable, posting a -33.6% profit margin.
Key Findings
Debt-to-equity ratio of 0.11 indicates a conservative balance sheet with 176M in cash.
The company is unprofitable with a -33.6% profit margin. The path to breakeven will be the key catalyst.
Free cash flow is -2M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Sector dynamics: monitor MEDICAL INSTRUMENTS & SUPPLIES industry trends, competitive moves, and regulatory changes that could impact STAAR Surgical Company.
Bottom Line
STAAR Surgical Company offers an attractive blend of growth (18% revenue expansion) and improving fundamentals. The company is transitioning from pure growth to profitable growth, a critical inflection point. Watch for sustained margin expansion as the key signal.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions(39 last 3 months)
Data sourced from SEC Form 4 filings
Last updated: 11:33:40 AM
About STAAR Surgical Company(STAA)
NASDAQ
HEALTHCARE
MEDICAL INSTRUMENTS & SUPPLIES
USA
STAAR Surgical Company designs, develops, manufactures, markets and sells implantable eye lenses and supplemental delivery systems for placing the lenses in the eye. The company is headquartered in Lake Forest, California.